Screener / SEC EDGAR /CIK 0001819790 /10-K filed Feb 23, 2026, compared with Feb 25, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
Nasdaq Health care · Biotechnology

Tarsus Pharmaceuticals, Inc. TARS

We are a commercial stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. 10-K, Item 1

Headquarters
Irvine, CA
CEO
Bobak R. Azamian
Next results
around Feb 22, 2027
Compare with peers Embed

TARS among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 146.7%, above 98% of 154 peers (their median 10.4%) REVENUE GROWTH 146.7% · above 98% Operating margin: -102.0%, above 7% of 138 peers (their median 10.2%) OPERATING MARGIN -102.0% · above 7% Net margin: -102.9%, above 7% of 153 peers (their median 6.8%) NET MARGIN -102.9% · above 7% FCF margin: 4.8%, above 33% of 144 peers (their median 10.1%) FCF MARGIN 4.8% · above 33%
TARS Peer median Below the median

What changed

25 new risk paragraphs. 10-K filed Feb 23, 2026 against Feb 25, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

0facts worth reading about all 11 checks found nothing to note

  • Receivables +81.9% ($46.8M to $85.1M) vs revenue +146.7% ($183.0M to $451.4M), -64.8 pts apart
  • Cash from operations −$12.5M vs net income −$66.4M (FY ending Dec 31, 2025)
  • Inventory +66.9% ($2.6M to $4.4M) vs revenue +146.7% ($183.0M to $451.4M), -79.8 pts apart
8 more checks with nothing to note
  • Same auditor in both 10-Ks: Ernst & Young LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • The same matters as last year: Accrued Commercial and Government Rebates Impacted by Estimated Payer Mix
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

25 paragraphs in Risk Factors that were not in the 10-K filed Feb 25, 2025. Quoted as filed.

All 25 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
    Our future financial performance and our ability to develop, manufacture and commercialize our product candidates will depend, in part, on our ability to effectively manage any future growth, and our management may also have to
  2. Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
    Additionally, the U.S. government has made statements and taken certain actions including the imposition of tariffs, that have led to changes in U.S. and international trade policies towards China and other countries. It remains unclear what additional actions, if any, will be taken by the U.S. or other governments with respect to…
  3. Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
    We received approval by the FDA for XDEMVY for the treatment of Demodex blepharitis in the U.S. and began generating revenue from product sales during the third quarter of 2023. Our ability to become and remain profitable is heavily
  4. Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
    A further example of comprehensive and evolving regulatory requirements is data privacy regulations surrounding personal data and protected health information including the EU’s General Data Protection Regulation, or GDPR, which imposes strict requirements on controllers and processors of personal data, including special protections for…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$25.8M$17.4M$183.0M$451.4M
Net income−$62.1M−$135.9M−$115.6M−$66.4M
Operating cash flow−$49.0M−$117.5M−$83.0M−$12.5M
Free cash flow−$49.5M−$119.0M−$84.6M−$22.3M

Revenue, FY2020 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$451.4M ▲ 146.7% in FY2025

FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

4 filings in the last 30 days · SEC EDGAR

All filings

About the company

Tarsus Pharmaceuticals, Inc., Irvine, CA · from the 10-K filed Feb 23, 2026

We are a commercial stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. We launched XDEMVY® (lotilaner ophthalmic solution) 0.25%, formerly known as TP-03, for the treatment of Demodex blepharitis, in August 2023 after receiving U.S. Food and Drug Administration (“FDA”) approval in July 2023. Demodex blepharitis is caused by the infestation of Demodex mites.

Headquarters
Irvine, CA
Country
United States
Reports in
USD
Listed on
Nasdaq
Fiscal year ends
December 31
Last results
Nov 3, 2026
Incorporated in
DE

Email alerts

Sources

The 10-K filed Feb 23, 2026 (open at SEC), compared with the 10-K filed Feb 25, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/TARS/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.